News

Cognition Therapeutics Inc. (NASDAQ:CGTX) saw its stock climb sharply by 75% following a productive end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) concerning its Alzheimer’s ...
If you read any research about Alzheimer’s disease, two proteins are going to be your main characters. There’s amyloid-β, ...